Navigation Links
Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
Date:10/12/2009

SEATTLE, Oct. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark and Pedro Granadillo have been elected to the Company's Board of Directors. Mr. Clark is currently head of global product strategy and chief marketing officer at Roche, Pharma Division, and, beginning January 1, 2010, he will be chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group. Mr. Granadillo, now retired, was most recently senior vice president of global manufacturing and human resources at Eli Lilly & Company.

"We are pleased to welcome Ian and Pedro to Dendreon's Board of Directors. Their industry leadership experience commercializing significant oncology products and managing large scale pharmaceutical manufacturing facilities make them ideal additions to our Board of Directors as we expand from a research organization into a commercial enterprise," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Their commercial expertise will strengthen the existing team at Dendreon as we prepare for U.S. Food and Drug Administration approval and the launch of PROVENGE® (sipuleucel-T) next year."

Mr. Clark previously was executive vice president of commercial operations and senior vice president of oncology commercial operations for Genentech's BioOncology business unit, which focused on global commercialization of the company's diverse oncology pipeline, including Avastin®, Rituxan® and Herceptin®. Prior to his time at Genentech, Mr. Clark was president of Novartis Canada and chief operating officer of Novartis United Kingdom. Mr. Clark received a B.S. in biological sciences from Southampton University in the United Kingdom.

Mr. Granadillo worked at Eli Lilly & Company for over thirty years in total, serving in roles such as vice president of human resources, vice president of pharmaceutical manufacturing, executive director of product operations and director of manufacturing strategy development. As the company's top executive for both manufacturing and human resources, Mr. Granadillo was responsible for the overall management of an extensive network of pharmaceutical manufacturing facilities and for policies affecting the company's global workforce of more than 43,000 employees. Mr. Granadillo received a B.S. in industrial engineering from Purdue University. He currently serves on the Board of Directors of Haemonetics Corporation, Nile Therapeutics and Tigris Pharmaceuticals.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
(Date:5/24/2016)... May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... on advancing renal care, today announced that Jeffrey ... in the following schedule of investor conferences. Where applicable, ... at http://ir.nxstage.com/ .   ... Conference NY, NY           Friday, June 10, 2016 1:30 ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living with ... worldwide. On Sunday, June 5, 2016, communities around the world will gather to recognize ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the ... Senior Living (SHSL) may not share those same worries thanks to a new ... year, while holding the line on increasing their contributions, including premiums, deductibles and the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial start of ... sharing tips to make sure your family and vehicle are ready to hit the ... may be 439 deaths and an additional 50,500 serious injuries from motor vehicle crashes ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... comprehensive treatment for eating disorders, is opening a brand new child and adolescent ... ages 8-17 and their families with even more specialized eating disorder treatment and ...
Breaking Medicine News(10 mins):